BMYBristol-Myers SquibbRunning, no new patients
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Hepatocellular Carcinoma · Liver Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 545 (final count)
- Started
- Apr 18, 2018
- Main results expected
- May 27, 2026
- Fully finished
- May 27, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence-free Survival (RFS)
Measured over: Up to 49 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03383458 · record last updated 2026-07-31 · checked 2026-11-09 15:42 UTC